Novel Coronavirus (SARS-CoV-2/COVID-19)
In an open letter, the AHA, American Medical Association and American Nurses Association thanked health care professionals for their dedication and sacrifices this year and urged them to continue their battle against COVID-19 by taking a vaccine and sharing their experience with others.
Ahead of a Dec. 17 meeting of its Vaccines and Related Biological Products Advisory Committee, the Food and Drug Administration released a briefing document confirming Moderna’s data on the safety and efficacy of the mRNA-1273 COVID-19 vaccine candidate.
December 15, 2020
An open letter to all health care professionals:
A bipartisan group of senators and representatives yesterday released legislative text for both the Emergency Coronavirus Relief Act of 2020, a $748 billion COVID-19 relief package that boosts funding for health care providers, vaccines and testing, and the Bipartisan State and Local Support and…
Combining the anti-inflammatory drug baricitinib with the antiviral drug remdesivir reduced the median recovery time for hospitalized COVID-19 patients from eight to seven days, according to clinical trial results published in the New England Journal of Medicine.
The Department of Health and Human Services Dec. 11 announced it would purchase from Moderna 100 million additional doses of its mRNA-1273 COVID-19 vaccine candidate.
Following the Food and Drug Administration’s Dec. 11 emergency use authorization of Pfizer, Inc.’s BNT162b2 mRNA COVID-19 vaccine, AHA released a Special Bulletin with important details for hospitals and health systems.
It was not at all the year I expected, and it certainly wasn’t the year any of us wanted. But, through it all, I continually found inspiration. Even now in the uncertainty of what 2021 will bring, I’m reassured knowing that no matter what, the teams who power our hospitals and health systems across…
The Food and Drug Administration late last night granted an emergency use authorization (EUA) to Pfizer, Inc. for its BNT162b2 mRNA COVID-19 vaccine, paving the way for its immediate administration across the country. Health care workers and nursing home residents will receive first priority and…
The Food and Drug Administration today granted an emergency use authorization to Pfizer, Inc. for its BNT162b2 mRNA COVID-19 vaccine, paving the way for its immediate administration across the country. The vaccine is administered in two doses, 21 days apart, and requires ultracold (minus-70 degrees…